ReviewMedical sciences (Basel, Switzerland)2018
Diagnosis of Idiopathic Pulmonary Fibrosis: Differential Diagnosis.
Review in Medical sciences (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 44 citations in OpenAlex.
- Review
- Atomic force microscopy-based nanomechanical signatures as cancer biomarkers in a nutshell.FEBS letters · 2026Review
- Atomic Force Microscopy-Based Nanomechanical Signatures for Staging Classification and Drug Response in Pulmonary Fibrosis.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Mesenchymal stem cells-extracellular vesicles alleviate pulmonary fibrosis by regulating immunomodulators.World journal of stem cells · 2024Article
- Assessing Lung Fibrosis with ML-Assisted Minimally Invasive OCT Imaging.Diagnostics (Basel, Switzerland) · 2024Article
- Idiopathic Pulmonary Fibrosis in a Young Adult: A Rare Presentation and Management Challenges.Cureus · 2023Article
- Stromal inflammation, fibrosis and cancer: An old intuition with promising potential.World journal of clinical oncology · 2023Review
- Idiopathic pulmonary fibrosis is more strongly associated with coronary artery disease than chronic obstructive pulmonary disease.Respiratory medicine · 2023Article
- Epigenetics Approaches toward Precision Medicine for Idiopathic Pulmonary Fibrosis: Focus on DNA Methylation.Biomedicines · 2023Review
- Wilms Tumor 1-Driven Fibroblast Activation and Subpleural Thickening in Idiopathic Pulmonary Fibrosis.International journal of molecular sciences · 2023Review
- FibroVit-Vision transformer-based framework for detection and classification of pulmonary fibrosis from chest CT images.Frontiers in medicine · 2023Article
- Cell-Specific Response of NSIP- and IPF-Derived Fibroblasts to the Modification of the Elasticity, Biological Properties, and 3D Architecture of the Substrate.International journal of molecular sciences · 2022Article
- Fish Oil Nanoemulsion Supplementation Attenuates Bleomycin-Induced Pulmonary Fibrosis BALB/c Mice.Nanomaterials (Basel, Switzerland) · 2022Article
- Discrimination between NSIP- and IPF-Derived Fibroblasts Based on Multi-Parameter Characterization of Their Growth, Morphology and Physic-Chemical Properties.International journal of molecular sciences · 2022Article
- Gut Microbiome and Organ Fibrosis.Nutrients · 2022Review
- Idiopathic pleuroparenchymal fibroelastosis: first case report in Lebanon.Journal of surgical case reports · 2021Article
- The Role of Radiology in Progressive Fibrosing Interstitial Lung Disease.Frontiers in medicine · 2021Review
- Clinical and Functional Characteristics of Patients with Unclassifiable Interstitial Lung Disease (uILD): Long-Term Follow-Up Data from European IPF Registry (eurIPFreg).Journal of clinical medicine · 2020Article
- Idiopathic pulmonary fibrosis and occupational risk factors.La Medicina del lavoro · 2019Article
- Highlights of thoracic oncology from the 2018 ERS International Congress.ERJ open research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fibrotic interstitial lung disease of unknown origin with a characteristic imaging and histologic pattern called usual interstitial pneumonia (UIP). The diagnosis of IPF is a complex procedure that requires the support of various specialists, who must integrate clinical, radiological, and histological data. The multidisciplinary team (MDT) has become the new gold standard to diagnose and manage the disease, increasing the accuracy and agreement of the diagnosis between different centers. It is mandatory to exclude nonspecific interstitial pneumonia or other diseases that can cause the UIP pattern, particularly drugs or exposure diseases, including chronic hypersensitivity pneumonitis or systemic autoimmune disease. The role of the MDT is also to decide who could need a biopsy or to review patient diagnoses at regular intervals in those with additional information or unexpected evolution. This review provides updated information to achieve a proper IPF diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.